Business Wire

STARLUX Airlines and Etihad Airways Launch Codeshare Partnership

4.6.2025 10:37:00 CEST | Business Wire | Press Release

Share

Taiwan-based luxury carrier STARLUX Airlines today announced a strategic codeshare agreement with Abu Dhabi-based Etihad Airways, enhancing connectivity for the passengers of both airlines across their respective networks. The agreement, formalized at the 81st International Air Transport Association (IATA) Annual General Meeting in New Delhi, marks a major step in STARLUX’s international expansion strategy and provides travelers with improved access to Europe via the Middle East.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603188795/en/

STARLUX Airlines and Etihad Airlines launch codeshare partnership

Under this partnership, STARLUX passengers will soon be able to book codeshare flights with Etihad Airways, via STARLUX’s official website and sales channels, enabling seamless connections from Taipei to Europe through Abu Dhabi. Travelers can also book itineraries departing from any STARLUX origin point, connecting to Etihad-operated codeshare flights to Abu Dhabi, with onward service to European destinations such as Prague, Madrid, and Barcelona. At the same time, Etihad passengers will enjoy streamlined access to STARLUX’s Asia-Pacific network with, smooth connections via Taipei to key cities in Japan—including Nagoya, Sapporo, and Fukuoka—further expanding access to STARLUX’s diverse Asia-Pacific network.

The codeshare arrangement simplifies travel by allowing guests to make a single booking with one check-in process at the departure airport, along with the added convenience of automatic baggage transfer to their final destination. Both airlines will carry out joint sales and marketing initiatives in Taiwan, and plan to launch a reciprocal frequent flyer program partnership by the end of the year.

“Our partnership with Etihad Airways marks a significant milestone in STARLUX Airlines’ global expansion, laying the foundation for future European routes,” said Simon Liu, Chief Strategy Officer of STARLUX Airlines. “As one of the Middle East’s leading carriers, Etihad is globally recognized for its innovation and premium service—values that strongly align with the STARLUX brand. By leveraging Abu Dhabi’s role as a major hub, this codeshare allows us to rapidly extend our network into Europe, offering passengers a wider range of travel options. We also look forward to deepening collaboration on mileage accrual and premium services to ensure an exceptional experience for customers.”

Arik De, Chief Revenue and Commercial Officer at Etihad Airways, said: “This partnership with STARLUX Airlines opens new market opportunities in Northeast Asia, giving our customers access to Japan's key business and leisure destinations through Taipei. STARLUX Airlines' reputation for premium service aligns perfectly with our standards, and together we're offering travellers more choice and convenience when connecting across three continents.”

STARLUX Airlines currently operates 32 routes across 27 destinations, featuring a robust Asian network while steadily expanding its footprint in North America with service to Los Angeles, San Francisco, and Seattle. On June 2, the airline launched its newest route to Ontario, California, with four weekly flights, further strengthening its presence on the U.S. West Coast. In February 2026, STARLUX is scheduled to launch its fifth U.S. destination—Phoenix—further enhancing its transpacific network. The newly signed codeshare partnership with Etihad Airways marks another key milestone in STARLUX’s international growth, enhancing global connectivity and delivering a seamless and elevated travel experience for passengers worldwide.

For more details, visit www.starlux-airlines.com or www.etihad.com.

About STARLUX Airlines

Founded on the philosophy that luxury should be available to everyone, not just the elite, Taiwan-based STARLUX is a boutique international airline serving a total of 32 routes from Taiwan to the US, Japan, Macau, Vietnam, Thailand, Philippines, Malaysia, and Singapore. STARLUX passengers traveling between Asia and North America are able to enjoy an easy transfer in Taipei with its four US routes: Taipei-Los Angeles, Taipei-San Francisco, Taipei-Seattle and Taipei-Ontario. In February 2026, STARLUX will launch its fifth U.S. destination—Phoenix, further strengthening its transpacific network. STARLUX prioritizes safety and offers unparalleled service with the goal of making flying a truly luxurious and unforgettable experience. For more information, visit https://www.starlux-airlines.com/en-US, or on our US social channels Facebook and Instagram.

About Etihad Airways

Etihad Airways, the national airline of the UAE, was formed in 2003 and quickly went on to become one of the world’s leading airlines. From its home in Abu Dhabi, Etihad flies to passenger and cargo destinations in the Middle East, Africa, Europe, Asia, Australia, and North America. Together with Etihad’s codeshare partners, Etihad’s network offers access to hundreds of international destinations. In recent years, Etihad has received numerous awards for its superior service and products, cargo offering, loyalty programme and more. To learn more, visit etihad.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250603188795/en/

Contacts

Media Contacts:
Mary Placido, SKC, Inc.
(415) 218-3627
mary@skc-pr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye